Phibro Animal Health Q4 Revenue Up 39%
Phibro Animal Health (NASDAQ:PAHC), a veterinary pharmaceutical and nutrition provider, reported earnings for Q4 FY2025 on August 27, 2025, covering the three months ending June 30. Driven by its largest-ever acquisition and strong international appetite for its medicated feed additives, the company’s sales, adjusted earnings, and profit margins all surpassed expectations. GAAP revenue reached $378.7 million, up 39% from the previous year. Adjusted diluted earnings per share (EPS) climbed to $0.57 from $0.41, also beating consensus expectations. Management described the result as a step-change, reflecting both solid underlying product demand and successful integration of new product lines, though a decline in gross margin showed that rising input and distribution costs remain a concern.
Phibro Animal Health manufactures and sells products that support animal health and nutrition across more than 90 countries. Its main product lines include medicated feed additives, which help prevent disease in livestock; nutritional specialty products that enhance animal health; and vaccines to combat specific animal diseases. The company’s clients include food producers, veterinarians, and animal health distributors.
Recently, Phibro has focused on expanding its reach and product portfolio through acquisitions and global growth. The October 2024 purchase of Zoetis's medicated feed additive portfolio added 37 products and six new manufacturing sites to its business. Success in this market relies on regulatory compliance, strong product innovation, and a global presence, with about 55% of animal health sales coming from outside the United States.
Source Fool.com
